Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
This phase III trial compares the effect of adding sonrotoclax to zanubrutinib versus zanubrutinib alone for the treatment of patients with untreated chronic lymphoblastic leukemia (CLL)/small lymphocytic lymphoma (SLL). Sonrotoclax is in …
- Sanford Bismarck Medical Center — Bismarck, North Dakota
- Essentia Health Cancer Center-South University Clinic — Fargo, North Dakota
- Sanford Broadway Medical Center — Fargo, North Dakota
- Sanford Roger Maris Cancer Center — Fargo, North Dakota